[Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)]
- PMID: 16447768
[Mutational and clinical features of Japanese patients with dysferlinopathy (Miyoshi myopathy and limb girdle muscular dystrophy type 2B)]
Abstract
Mutations in the dysferlin gene cause both Miyoshi myopathy (MM) and limb girdle muscular dystrophy 2B (LGMD2B). We examined patients with dysferlinopathy in Japan, and identified 28 and 12 different mutations respectively in MM and LGMD2B patients. The mean age at onset of the patients with MM was 22 +/- 9 years (range 12-48 years) and that of the patients with LGMD2B was 26 +/- 10 years (range 11-43 years). On the average, the first use of a cane was at 33 years (14 years after the onset) for MM and 39 years (15 years after onset) for LGMD 2B. Patients became wheelchair-bound at 41 years (21 years after onset) in MM and 45 years (21 years after onset) for LGMD2B. The mean maximum serum CK level at any age of the patients was 5,829 +/- 4,273 IU/l (range 1,289-12,566 IU/l ) for MM and 3,787 +/- 2,493 IU/l (627-10,000 IU/l) for LGMD2B: in both disorders, the serum CK level fell in proportion to the duration of the illness. We have identified four common four mutations (C1939G, G3370T, 3746delG, and 4870delT) in Japanese patients with MM, accounting for 48 percent of all MM mutations in this population. Two of the four mutations (G3370T, and 4870delT) accounted for 52 percent of the mutations in LGMD2B patients, while the 3746delG mutation was not found in patients with LGMD2B. The G3370T mutation may be associated with a milder form of MM and LGMD2B. By contrast, the G3510A mutation appears to be associated with a severe form of MM.
Similar articles
-
Dysferlin mutations in Japanese Miyoshi myopathy: relationship to phenotype.Neurology. 2003 Jun 10;60(11):1799-804. doi: 10.1212/01.wnl.0000068333.43005.12. Neurology. 2003. PMID: 12796534
-
Dysferlinopathy: a clinical and histopathological study of 28 patients from India.Neurol India. 2008 Jul-Sep;56(3):379-85; discussion 386-7. doi: 10.4103/0028-3886.40964. Neurol India. 2008. PMID: 18974568
-
Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B.J Neurol Neurosurg Psychiatry. 2013 Apr;84(4):433-40. doi: 10.1136/jnnp-2011-301339. Epub 2012 Dec 15. J Neurol Neurosurg Psychiatry. 2013. PMID: 23243261 Free PMC article.
-
[Miyoshi distal muscular dystrophy (Miyoshi myopathy)].Brain Nerve. 2011 Feb;63(2):147-56. Brain Nerve. 2011. PMID: 21301039 Review. Japanese.
-
Limb-Girdle Muscular Dystrophy 2B and Miyoshi Presentations of Dysferlinopathy.Am J Med Sci. 2017 May;353(5):484-491. doi: 10.1016/j.amjms.2016.05.024. Epub 2016 May 30. Am J Med Sci. 2017. PMID: 28502335 Review.
Cited by
-
CAR T-Cell Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma with Progressive Muscular Dystrophy: A Case Report.Onco Targets Ther. 2022 Apr 8;15:361-366. doi: 10.2147/OTT.S352760. eCollection 2022. Onco Targets Ther. 2022. PMID: 35422632 Free PMC article.
-
Analysis of Exon Skipping Applicability for Dysferlinopathies.Cells. 2025 Jan 24;14(3):177. doi: 10.3390/cells14030177. Cells. 2025. PMID: 39936969 Free PMC article. Review.
-
The Clinicopathological Distinction between Immune-Mediated Necrotizing Myopathy and Limb-Girdle Muscular Dystrophy R2: Key Points to Prevent Misdiagnosis.J Clin Med. 2022 Nov 5;11(21):6566. doi: 10.3390/jcm11216566. J Clin Med. 2022. PMID: 36362794 Free PMC article.
-
Portrait of Dysferlinopathy: Diagnosis and Development of Therapy.J Clin Med. 2023 Sep 16;12(18):6011. doi: 10.3390/jcm12186011. J Clin Med. 2023. PMID: 37762951 Free PMC article. Review.
-
Limb Girdle Muscular Dystrophy Type 2B (LGMD2B): Diagnosis and Therapeutic Possibilities.Int J Mol Sci. 2024 May 21;25(11):5572. doi: 10.3390/ijms25115572. Int J Mol Sci. 2024. PMID: 38891760 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials